Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | IAPP | P10997 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798814 | 1.00 | AKR1B1 (0.42) | AKR1B1IDO1ALDH1A1HSPA5SERPINE1 | |
| SCHEMBL28302378 | 0.84 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL2385885 | 0.79 | ALDH1A1 (0.57) | AKR1B1IDO1ALDH1A1HSPA5TYR | |
| SCHEMBL17599139 | 0.78 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2CYP2D6TSHRHIF1A | |
| Ammonia Solution, Strong SCHEMBL22266087 | 0.78 | ALDH1A1 (0.55) | AKR1B1IDO1ALDH1A1HSPA5TYR | |
| SCHEMBL20673384 | 0.77 | BACE1 (0.32) | AKR1B1 | |
| Acetic Acid SCHEMBL7569175 | 0.76 | ALDH1A1 (0.58) | AKR1B1IDO1ALDH1A1HSPA5TYR | |
| SCHEMBL674324 | 0.74 | HSPA5 (0.54) | AKR1B1IDO1ALDH1A1HSPA5CYP2D6 | |
| SCHEMBL20512217 | 0.73 | HSPA5 (0.48) | AKR1B1IDO1ALDH1A1HSPA5CYP2D6 | |
| SCHEMBL10850944 | 0.73 | HSPA5 (0.48) | AKR1B1IDO1ALDH1A1HSPA5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-3860999-B9 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3860999-B1 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-3625233-B9 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3625233-B9 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3625233-B1 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3625233-B1 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS INC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-3676247-B1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-10500211-B2 | Beta-lactamase inhibitors and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10280161-B2 | Aztreonam derivatives and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| WO-2019070595-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019070595-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-01-24 | — | — | US | disclosed |
| WO-2018208557-A1 | 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROP NOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS | ARIXA PHARMACEUTICALS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-10085999-B1 | Beta-lactamase inhibitors and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280161-B2 | Aztreonam derivatives and uses thereof | MGAM, ABCG2, SI | AKR1B1 1122/4885IDO1 2883/4885ALDH1A1 1229/4885 |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | AKR1B1 1122/4885IDO1 2883/4885ALDH1A1 1229/4885 |
| US-20190022102-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | MGAM, LCT, CMBL | AKR1B1 2207/4885IDO1 2786/4885ALDH1A1 834/4885 |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | AKR1B1 1122/4885IDO1 2883/4885ALDH1A1 1229/4885 |
| US-20230201218-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | AKR1B1 1770/4885IDO1 2242/4885ALDH1A1 830/4885 |
| US-10085999-B1 | Beta-lactamase inhibitors and uses thereof | GAA, LCT, MGAM | AKR1B1 1770/4885IDO1 2242/4885ALDH1A1 830/4885 |
| US-10500211-B2 | Beta-lactamase inhibitors and uses thereof | GAA, LCT, MGAM | AKR1B1 1770/4885IDO1 2242/4885ALDH1A1 830/4885 |
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | AKR1B1 1770/4885IDO1 2242/4885ALDH1A1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.